{"classes":[{"categories":[{"measurements":[{"comment":"The upper bound of the 95% confidence interval was not reached due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"160.0","upperLimit":"NA","value":"825.5"},{"comment":"The upper bound of the 95% confidence interval was not reached due to insufficient number of participants with events.","groupId":"OG001","lowerLimit":"34.0","upperLimit":"NA","value":"116.5"},{"comment":"The lower and upper bounds of the 95% confidence interval were not reached due to insufficient number of participants with events.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"113.0"},{"comment":"The median and upper bound of the 95% confidence interval were not reached due to insufficient number of participants with events.","groupId":"OG004","lowerLimit":"127.0","upperLimit":"NA","value":"NA"},{"comment":"The upper bound of the 95% confidence interval was not reached due to insufficient number of participants with events.","groupId":"OG005","lowerLimit":"80.0","upperLimit":"NA","value":"634.0"},{"comment":"The median and upper bound of the 95% confidence interval were not reached due to insufficient number of participants with events.","groupId":"OG006","lowerLimit":"57.0","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"2"}],"units":"Participants"}],"description":"Interval of time from date of first observed complete or partial response per Lugano 2014 criteria (Cheson BD et al. J Clin Oncology 2014;32(27):3059-68) to the date of documented disease progression or death due to any cause, where disease progression is defined by Lugano 2014 criteria (Cheson BD et al. J Clin Oncology 2014;32(27):3059-68) as progressive metabolic disease (increase in fluorodeoxyglucose \\[FDG\\] uptake from baseline or new FDG-avid foci consistent with lymphoma) or progressive radiologic response (increase in the product of perpendicular diameters of a single node by ≥ 50% or emergence of a new lesion)","dispersionType":"95% Confidence Interval","groups":[{"description":"VRx-3996: 10 mg twice daily (BID) valganciclovir: 900 mg BID","id":"OG000","title":"Phase 1b Dose Escalation Cohort 1"},{"description":"VRx-3996: 5 mg BID valganciclovir: 450 mg BID","id":"OG001","title":"Phase 1b Dose Escalation Cohort 2a"},{"description":"VRx-3996: 10 mg once daily (QD) valganciclovir: 450 mg BID","id":"OG002","title":"Phase 1b Dose Escalation Cohort 2b"},{"description":"VRx-3996: 10 mg QD valganciclovir: 900 mg QD","id":"OG003","title":"Phase 1b Dose Escalation Cohort 2c"},{"description":"VRx-3996: 20 mg QD on Days 1 to 4/week valganciclovir: 900 mg QD","id":"OG004","title":"Phase 1b Dose Escalation Cohort 3"},{"description":"VRx-3996 (RP2D: 20 mg QD on Days 1 to 4/week) and valganciclovir (RP2D: 900 mg QD)","id":"OG005","title":"Phase 2 Dose Expansion - Capsule"},{"description":"VRx-3996 (RP2D: 20 mg QD on Days 1 to 4/week) and valganciclovir (RP2D: 900 mg QD)","id":"OG006","title":"Phase 2 Dose Expansion - Tablet"}],"paramType":"MEDIAN","populationDescription":"Patients who achieved a CR or PR. Valganciclovir dosage reductions were allowed for participants with renal impairment at study entry or during study treatment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 2 years","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"days"}